Capvaxive

SOURCE- Jama10 22/29.2024, Yayoo

Generic name: pneumococcal 21-valent conjugate vaccine

Capvaxive (pneumococcal 21-valent conjugate vaccine) is a single-dose vaccine that may be used to protect adults aged 18 years and older against invasive pneumococcal disease and pneumonia caused by certain types of bacteria called pneumococcus.

These bacteria can cause many types of illnesses, which can be severe, such as infections in:

• your lungs (pneumonia)
• the area around your brain and spinal cord (meningitis)
• your blood (bacteremia).

You cannot get pneumococcal disease from Capvaxive but Capvaxive might not protect everyone who gets the vaccine.

Capvaxive works by stimulating cells in your immune system to kill bacteria. It works against 22 Streptococci pneumoniae serotypes (serotype 15B has a similar molecular structure to serotype 15C) using opsonization (an immune process where opsonins, such as antibodies, are used to tag foreign pathogens for elimination by phagocytes) to target the specific S. pneumoniae serotypes. Capvaxive protects against 8 serotypes not covered by other pneumococcal shots.

Capvaxive was FDA-approved on June 17, 2024. The indication for pneumonia prevention is approved under the accelerated approval designation based on immune responses. Continued approval for this indication may be contingent upon continued benefits reported in further clinical trials.